| Trial ID: | L4190 |
| Source ID: | NCT03919617
|
| Associated Drug: |
Remd-477
|
| Title: |
Metabolic Pathways of GRA in Patients With Type 1 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 1 Diabetes Mellitus
|
| Interventions: |
DRUG: REMD-477
|
| Outcome Measures: |
Primary: Change in Beta-hydoxybutyrate (BHB) Level, The change from baseline in peak BHB production as measured by the insulin withdrawal challenge., 4-Weeks|Rate of De Novo Lipogenesis (DNL), Change from baseline in disrupted glucagon signaling as measured by the glucose challenge and deuterated water ingestion., 4-Weeks|Rate of Hepatic Steatosis, Changes from baseline in hepatic steatosis as measured by the glucose challenge and deuterated water ingestion., 4-Weeks|Rate of Resting Energy Expenditure (REE), Change from baseline REE as measured by the glucose challenge and deuterated water ingestion., 4-Weeks |
|
| Sponsor/Collaborators: |
Sponsor: University of California, San Diego | Collaborators: REMD Biotherapeutics, Inc.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1|PHASE2
|
| Enrollment: |
4
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2019-07-01
|
| Completion Date: |
2022-05-31
|
| Results First Posted: |
|
| Last Update Posted: |
2022-07-15
|
| Locations: |
UC San Diego Altman Clinical & Translational Research Institute, La Jolla, California, 92037, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT03919617
|
